Alps Group launches drug-interaction testing unit
Herbal and supplement manufacturers, pharmaceutical companies and research institutions are named as intended customers for the testing service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alps Group Inc launched its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing as its first commercial service. The testing covers seven major enzyme isoforms: CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2B6 and CYP2E1. Alps states these enzymes collectively metabolize approximately 90% of marketed clinical drugs.
PCI will make the service available to herbal and supplement manufacturers, pharmaceutical companies and research institutions. FDA and EMA guidelines recommend CYP inhibition evaluation for clinical and botanical drugs. The unit joins Alps’ B2B laboratory services, which include capabilities across precision oncology, genomics and translational research.
Key Figures
Key Terms
Pharmaco-Interaction (PCI) technical
CYP450 inhibitory IC50 testing technical
cytochrome P450 (CYP450) technical
enzyme isoforms technical
LC-MS/MS Triple Quadrupole technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who can use ALPS's CYP450 testing service?
Do FDA and EMA guidelines recommend CYP inhibition testing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-42915
Alps Group Inc
(Registrant’s Name)
Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)
No. 1, Jalan 1/68F, Jalan Tun Razak
50400 Kuala Lumpur
Wilayah Persekutuan, Malaysia
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information Contained in this Form 6-K Report
Attached hereto as Exhibit 99.1 is a press release dated November 12, 2026 issued by Alps Group Inc announcing the launch of its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing debuting as its first commercial service offering.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated November 12, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alps Group Inc | ||
| Date: November 12, 2026 | By: | /s/ Dr. Seng Kong Tham |
| Name: | Dr. Seng Kong Tham | |
| Title: | Chief Executive Officer and Director | |
| 3 |
Exhibit 99.1
Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing
PCI Positions MyGenome as Southeast Asia’s Reference Laboratory for Drug Interaction Safety Science
KUALA LUMPUR, Malaysia – November 12, 2026 – Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced the launch of its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing debuting as its first commercial service offering.
The MyGenome laboratory facility in Kuala Lumpur, Malaysia, home to the newly launched Pharmaco-Interaction (PCI) unit.
PCI will start with cytochrome P450 (CYP450) inhibitory IC50 testing across seven major enzyme isoforms (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2B6, and CYP2E1), collectively responsible for metabolizing approximately 90% of marketed clinical drugs, supporting safe use, regulatory compliance, and consumer confidence. FDA and EMA guidelines recommend CYP inhibition evaluation for clinical and botanical drugs. PCI will make this service available to herbal and supplement manufacturers, pharmaceutical companies, and research institutions.
“Every service we launch is a building block toward becoming Southeast Asia’s integrated life sciences reference platform,” said Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc. “The region has a significant and growing herbal and botanical products industry, yet access to accredited CYP inhibition testing has remained limited. PCI addresses that gap converting our scientific infrastructure into a revenue-generating capability that meets the regulatory standards already demanded by the market.”
“The assumption that all natural products are inherently safe, especially in consumption with prescription drugs, is one of the most persistent misconceptions in healthcare,” said Professor Nik Soriani, PCI Scientific Lead at MyGenome. “CYP450 inhibition testing is already recommended by the FDA and EMA for clinical and botanical products. PCI intends to make that standard accessible to manufacturers and researchers across Southeast Asia. We are building the reference laboratory Southeast Asia has been missing.”
LC-MS/MS Triple Quadrupole used for CYP450 inhibitory IC50 testing across seven major enzyme isoforms at Alps Group Inc’s MyGenome subsidiary.
PCI joins a growing suite of high-value B2B services within Alps’ laboratory portfolio, as the Company expands its capabilities across precision oncology, genomics, and translational research, with the goal of establishing Malaysia as a regional hub for ethical life science services.
About Alps Group Inc
Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Alps Group Inc
Investor Relations
Phone: +60 3-2163 1113
Email: investorrelations@alpsmedical.com